CYP19A1 and breast cancer: The therapeutic implications of ESR1 mutations were demonstrated in a phase 3 clinical trial (PADA-1) in which metastatic hormone receptor-positive (ER/PR+) breast cancer patients received first-line therapy with aromatase inhibitors and Palbociclib.